Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have demonstrated a strong activity of rituximab alone in indolent B non-Hodgkin lymphoma, especially in patients with follicular lymphoma. The most utilized dose-schedule is 375 mg/m2 weekly×4. The association with chemotherapy or with interferon-alpha increases Rituximab efficacy. More recently, Rituximab have showed activity also in diffuse large cell lymphoma, mantle cell lymphoma and in other B-malignancies. Good results have also been obtained utilizing Rituximab for in vivo purging. However, we are still far from having found a definite position for Rituximab in the treatment of lymphoproliferative disorders. The aim of future studies should be to develop new strategies that will hopefully produce the most effective Rituximab-based regimens in order to find the Rituximab key position in the treatment of B-malignancies
Treatment of B-cell low-grade non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab / Sacchi, Stefano; Federico, Massimo; G., Dastoli; C., Fiorani; G., Vinci; V., Clò; B., Casolari. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - STAMPA. - 37(1)(2001), pp. 13-25. [10.1016/S1040-8428(00)00069-X]
Data di pubblicazione: | 2001 | |
Titolo: | Treatment of B-cell low-grade non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. | |
Autore/i: | Sacchi, Stefano; Federico, Massimo; G., Dastoli; C., Fiorani; G., Vinci; V., Clò; B., Casolari | |
Autore/i UNIMORE: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/S1040-8428(00)00069-X | |
Rivista: | ||
Volume: | 37(1) | |
Pagina iniziale: | 13 | |
Pagina finale: | 25 | |
Codice identificativo ISI: | WOS:000166559800002 | |
Codice identificativo Scopus: | 2-s2.0-0035154779 | |
Codice identificativo Pubmed: | 11164715 | |
Citazione: | Treatment of B-cell low-grade non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab / Sacchi, Stefano; Federico, Massimo; G., Dastoli; C., Fiorani; G., Vinci; V., Clò; B., Casolari. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - STAMPA. - 37(1)(2001), pp. 13-25. [10.1016/S1040-8428(00)00069-X] | |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
Treatment of B-cell......pdf | Versione dell'editore (versione pubblicata) | Administrator Richiedi una copia |
Pubblicazioni consigliate

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris